课题基金 / 基金详情

Study of generation and dynamics of HIV enzymes essential for replication and structural design of their inhibitors

Study of generation and dynamics of HIV enzymes essential for replication and structural design of their inhibitors
研究 HIV 酶的生成和动力学,这些酶对于其抑制剂的复制和结构设计至关重要
批准号:
20390288
负责人:
MITSUYA Hiroaki
金额:
$11.9万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2008
资助国家:
日本
项目状态:
已结题
起止时间:
2008 至 2010

项目摘要

项目成果

MITSUYA Hiroaki的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
We reported in this study period that, through superinfection of cells with multiple HIV-1 strains and homologous recombination, HIV-1 can acquire high-level resistance against darunavir (DRV), to which HIV-1 hardly acquires resistance. We also identified cyclopentanyl-tetrahydrofuran-containing GRL-02031, which binds to HIV-1 protease in a bimodal way and exerts potent antiviral activity. Furthermore, we obtained GRL-0216A and -0286A with a macrocyclic ligand plus GRL-1388A and -1398A which contain a tetrahydropyrano-tetrahydrofuran moiety and exert potenta activity agaisnt multi-drug resistant varinats including DRV-resistant HIV-1 strains. We also ideintified GRL-0519A, which contains an oxatricyclic-tetrahydrofuran with potent anti-HIV activtiy agaisnt a wide spectrum of drug-resistant HIV-1s and potent activity to block the dimerization of HIV-1 portease monomers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors.
使用对多种常规蛋白酶抑制剂具有耐药性的临床 HIV-1 分离株的混合物,在体外选择高度地瑞纳韦耐药且具有复制能力的 HIV-1 变体。
DOI: --
发表时间: 2010
期刊: J Virol.
影响因子: --
作者: [Koh Y, Amano M, Towata T, Danish M, Leshchenko-Yashchuk S, Das D, Nakayama M, Tojo Y, Ghosh AK, Mitsuya H]
通讯作者: Mitsuya H
Potent activity of a nucleoside reverse transcriptase inhibitor, 4'-ethynyl-2-fluoro-2'-deoxyadenosine, against HIV-1 infection in Hu-PBMC-NOD/ SCID/JAK3null(NOJ)mouse model
核苷逆转录酶抑制剂 4-乙炔基-2-氟-2-脱氧腺苷在 Hu-PBMC-NOD/SCID/JAK3null(NOJ) 小鼠模型中对抗 HIV-1 感染的有效活性
DOI: --
发表时间: 2009
期刊: Antimicrob.Agents Chemother 53
影响因子: --
作者: [Hattori S, Mitsuye, H., et al.]
通讯作者: et al.
Mechanism of the Emergence of HIV-1 Variants Highly Resistaut to Darunavir
对达芦那韦高度耐药的 HIV-1 变异体的出现机制
DOI: --
发表时间: 2010
期刊:
影响因子: --
作者: [Yasuhiro Koh, M Aoki, M,Amano, H Ogata-Aoki, S Leschenko-Yashchuk, A Ghosh, H Mitsuya, Hiraoka K., 天野将之, Kurosawa H., Matthew L.Danish]
通讯作者: Matthew L.Danish
Structure-based Development of Antiviral Therapeutics for HIV-1 Infection and AIDS.
基于结构的 HIV-1 感染和艾滋病抗病毒治疗药物开发。
DOI: --
发表时间: 2008
期刊:
影响因子: --
作者: [Mitsuya, H.]
通讯作者: H.
48
    Study of mechanism of HIV resistance to integrase strand transfer inhibitors (INSTI) aiming at development of INSTI-resistance-repellant therapeutics
    Elucidation of the mechanism of HIV-1's drug resistance against protease inhibitors using crystal structure and thermodynamic analyses
    • 批准号:
      16K15520
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.16万
    • 财政年份:
      2016
    • 负责人:
      MITSUYA Hiroaki
    • 依托单位:
    The molecular mechanism of HIV-1's drug resistance against protease inhibitors including darunavir and the development of novel resistance-repelling protease inhibitors
    • 批准号:
      26293239
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $10.73万
    • 财政年份:
      2014
    • 负责人:
      MITSUYA Hiroaki
    • 依托单位:
    Structural analysis of HIV integrase multimerization and development of inhibitors of integrase interactions with cellular cofactos
    • 批准号:
      25670467
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.41万
    • 财政年份:
      2013
    • 负责人:
      MITSUYA Hiroaki
    • 依托单位:
    国内基金
    海外基金
    人类免疫缺陷病毒(HIV)总核酸检测试剂盒
    基于深度测序与SNV 芯片的HIV重复感染与毒株重组机制研究
    • 批准号:
      2026JJ81281
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      徐艳
    • 依托单位:
    HIV相关肺癌免疫微环境中关键免疫细胞亚群的功能特征与调控机制研究
    PGT123中和抗体修饰的工程化载肽囊泡疫苗通过诱导CD4+ T细胞极化在抗HIV感染中的应用和机制研究